SEC Form 4 · accession 0001094891-17-000219
PAVmed Inc. · PAVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Lishan Aklog
Officer — Chairman and CEO · Director · 10% Owner
HCFP/Capital Partners III LLC
10% Owner
Pavilion Venture Partners LLC
10% Owner
Period of report
Aug 21, 2017
Accepted (ET)
Aug 25, 2017 · 2:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001624326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2017 | P$0 | 7,500 | — | A | 47,377 | D | |
| Common StockF2 | Aug 22, 2017 | P$0 | 1,500 | — | A | 48,877 | D | |
| Common Stock | holding | — | — | — | 285 | I | By daughter | |
| Common Stock | holding | — | — | — | 300 | I | By son | |
| Common StockF3 | holding | — | — | — | 5,713,879 | I | By HCFP/Capital Partners III LLC | |
| Common StockF4 | holding | — | — | — | 2,520,532 | I | By Pavilion Venture Partners LLC | |
| Common StockF5 | holding | — | — | — | 87,020 | I | By HCFP Inc. | |
| Common StockF6 | holding | — | — | — | 125,000 | I | By HCFP/Capital Partners IIIB LLC | |
| Common StockF7 | holding | — | — | — | 20,000 | I | By HCFP/AG LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were purchased at a weighted average price of approximately $4.20 per share. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F2The shares were purchased at a weighted average price of approximately $4.18 per share. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.25, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F3Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
- F4Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
- F5Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
- F6Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
- F7Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.